References
- Taylor B. Drugs and Poisons Unit, Rural & Regional Health & Aged Care Services. Department of Human Services Victoria. June, 2006
- Aboltins C A, Allen P, Daffy J R. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Medical Journal of Australia 2005; 182(8)427
- Jenkinson R A, Clark N C, Fry C L, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005; 100: 197–205
- Luty J, O'Gara C, Sessay M. Is methadone too dangerous for opiate addiction?. British Medical Journal 2005; 331: 1352–1353
- Loo H W, Yam A KT, Tan T C, Peng Y P, Teoh L C. Severe upper limb complications from parenteral abuse of Subutex. Ann Acad Med Singapore 2005; 34: 575–578
- Auriacombe M, Fatseas M, Dubernet J, Daulouede J, Tignol J. French field experience with buprenorphine. American Journal on Addiction 2004; 13: S17–S28
- Feeney G FX, Fairweather P. Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Drug and Alcohol Review 2003; 22: 359–361
- Robinson G M, Dukes P D, Robinson B J, Cooke R R, Mahoney G N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug and Alcohol Dependence 1993; 33: 81–86
- Forsyth A JM, Farquhar D, Gemmell M, Shewan D, Davies J B. The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland). Drug and Alcohol Dependence 1993; 32: 277–280
- Singh R A, Mattoo S K, Malhotra A, Varma V K. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica 1992; 86: 46–48
- Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88(1)75–78
- Lintzeris N, Lenne M, Ritter A. Methadone injecting in Australia: a tale of two cities. Addiction 1999; 94(8)1175–1178
- Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence 2003; 69(2)175–181
- Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96(2)267–272
- Dietze P, Fitzgerald J. Interpreting changes in heroin supply in Melbourne: droughts, gluts or cycles?. Drug and Alcohol Review 2002; 21(3)295–303
- Cazorla C, Grenier de Cardenal D, Schuhmacher H, Thomas L, Wack A, May T, Rabaud C. Infectious complications and misuse of high-dose buprenorphine. Presse Med 2005; 34(10)719–724
- Topp L. Pharmaceutical diversion: accidental harm reduction?. Of Substance 2006; 4(2)6–9
- Lintzeris N, Strang J, Metrebian N, Byford S, Hallam C, Lee S, Zador D, RIOTT Group. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J 2006; 27: 3–28